Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2014

View Archived Issues

Novel S1P1 receptor ligands designed by Allergan

Scientists at Purdue Pharma divulge new opioid receptors ligands

Chinese companies disclose new PI3Kalpha inhibitors

Domainex reports promising preclinical data for lead compound in model of COPD

NIH funds phase II trial of NeuroSigma's eTNS System

Biosceptre raises funds for development of BIL-221-s

Insys Therapeutics completes human abuse study for dronabinol

CNX-013-B2, a pan-PPAR activator for diabetes and obesity

Biological characterization of a first-in-class, small-molecule, anticancer kinetochore inhibitor

Kyoto Pharmaceutical's PTP-1B inhibitor, a promising candidate for diabetes and obesity

Clinical results reported for TTP-399, a liver-selective GKA for type 2 diabetes

Beloranib granted orphan drug status in the E.U. for Prader-Willi syndrome

Evzio auto-injector available in the U.S. for emergency treatment of opioid overdose

Merck & Co. discloses new Mdm2 inhibitors

Sarepta Therapeutics reports long-term data from phase IIb study of eteplirsen

Quanticel prepares novel histone demethylase inhibitors

TransTech Pharma agrees with FDA on special protocol assessment for TTP-488

Givinostat shows activity in models of glioblastoma

MabVax Therapeutics and Telik finalize merger

Baxter acquires AesRx

NDA for Kythera Biopharmaceuticals' ATX-101 accepted

Glenmark initiates first-in-human trial of MPGES-1 inhibitor

Viamet reports new phase IIa data on VT-1161 in tinea pedis and acute vulvovaginal candidiasis

Bristol-Myers Squibb plans Q3 BLA for Opdivo in advanced melanoma

Takeda plans phase I study of ixazomib citrate in lupus nephritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...